Clinical trials: Malignancy, Hematologic, open to volunteers
Hematologic Malignancies, Solid Tumors
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study.
- Trial name
- NCT06925685
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Allogene Therapeutics
Core Binding Factor Alpha Subunits, Hematologic Neoplasms
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Background: Some blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with.
- Conditions
- Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
- Trial name
- NCT07524530
- Testing
- Cyclophosphamide, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Prophylactic DLI-X for Leukemia Relapse After HCT
The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo)…
- Conditions
- Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome
- Trial name
- NCT07254793
- Testing
- Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Arizona
Wide Spectrum of Diseases, Hematologic Diseases
Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors
Background: Researchers seek ways to study people s medical problems in order to teach and further general knowledge. The ability to assess and treat people with a wide range of diseases is critical to training people to be good…
- Trial name
- NCT04450927
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematologic Disease and Disorders, Donors
Screening for Hematology Branch Protocols
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.
- Conditions
- Hematologic Disease and Disorders, Donors, Healthy Volunteer
- Trial name
- NCT00001620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Neoplasms, Hematologic Neoplasms
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
This study will collect biological samples for use in research experiments aimed at better understanding the clinical features of certain diseases.
- Conditions
- Neoplasms, Hematologic Neoplasms, Healthy Volunteers
- Trial name
- NCT00071045
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pediatric Cancers, Hematologic Malignancies
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
Background: Gene therapy involves changing the genes inside the body s cells to stop disease. It is very closely regulated. People who have had this therapy may have problems months or even years later.
- Conditions
- Pediatric Cancers, Hematologic Malignancies, Solid Tumors
- Trial name
- NCT02315599
- Testing
- anti-CD19 CAR
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Neoplasms
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD).
- Trial name
- NCT04959175
- Testing
- Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers.
- Trial name
- NCT05436418
- Testing
- Melphalan, Sirolimus, Total Body Irradiation (TBI)
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HIV, Hematologic Malignancies
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Background: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a…
- Trial name
- NCT05470491
- Testing
- RIC, GVHD prophylaxis, allo HCT
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HLA/AAV Sensitization, Auto-immune Diseases
Real-world Clinical Effectiveness & Safety LV009, an in Vivo CAR-T for the Treatment of Hematologic Cancers, Auto-immune Diseases & HLA/ AAV Sensitization.
The study objective is to determine the real-world safety and effectiveness of LV009 therapy for 3 potential indications: (1) refractory or relapsed hematologic cancers (acute lymphoblastic Leukemia, B cell Lymphomas, multiple…
- Conditions
- HLA/AAV Sensitization, Auto-immune Diseases, Hematologic Cancers
- Trial name
- LV009 (NCT07873476)
- Testing
- LV009
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- Healthy Malaysia Association
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI
Lymphatic Diseases, Hematopoietic Malignancy
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units.
- Trial name
- NCT01451502
- Testing
- Umbilical Cord Blood (UCB)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant compared to estimated…
- Trial name
- NCT05711667
- Testing
- Biospecimen Collection, Letermovir
- Where
- 33 sites in United States
- Volunteers
- 105 people
- Sponsor
- Children's Oncology Group
Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
This study collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Solid Neoplasm
- Trial name
- NCT04242095
- Testing
- Biospecimen Collection, Medical Chart Review
- Where
- 629 sites in United States
- Volunteers
- 2,240 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hematologic Disease and Disorders, Malignancies
Outcome of HSCT in Children at Ramathibodi Hospital
Firstly, to study the treatment outcomes of hematopoietic stem cell transplantation (HSCT) in patients with hematologic diseases, cancers, and other conditions treated at the Department of Pediatrics, Faculty of Medicine…
- Conditions
- Hematologic Disease and Disorders, Malignancies, Genetic Diseases
- Trial name
- NCT07857746
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Mahidol University
Hematologic Malignancy, Leukemia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting.
- Conditions
- Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT06131801
- Testing
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Solid Tumors, Hematologic Cancers
Genomic Profiling in Cancer Patients
The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation.
- Trial name
- NCT01775072
- Testing
- molecular profiling of tumors, Clinical Germline Analysis
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center